文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
侵权投诉

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

The new england journal of medicine

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, M.D., Edith A. Perez, M.D., John Bryant, Ph.D., Vera J. Suman, Ph.D., Charles E. Geyer, Jr., M.D., Nancy E. Davidson, M.D., Elizabeth Tan-Chiu, M.D., Silvana Martino, D.O., Soonmyung Paik, M.D., Peter A. Kaufman, M.D., Sandra M. Swain, M.D., Thomas M. Pisansky, M.D.,

Louis Fehrenbacher, M.D., Leila A. Kutteh, M.D.,

Victor G. Vogel, M.D., Daniel W. Visscher, M.D., Greg Yothers, Ph.D., Robert B. Jenkins, M.D., Ph.D., Ann M. Brown, Sc.D., Shaker R. Dakhil, M.D.,

Eleftherios P. Mamounas, M.D., M.P.H., Wilma L. Lingle, Ph.D., Pamela M. Klein, M.D., James N. Ingle, M.D., and Norman Wolmark, M.D.

background

From the National Surgical AdjuvantBreast and Bowel Project, Pittsburgh(E.H.R., J.B., C.E.G., E.T.-C., S.P., S.M.S.,L.F., V.G.V., G.Y., A.M.B., E.P.M., N.W.);University of Kentucky, Lexington (E.H.R.);North Central Cancer Treatment Group,Rochester, Minn. (E.A.P., V.J.S., T.M.P.,L.A.K., D.W.V., R.B.J., S.R.D., W.L.L., J.N.I.);Mayo Clinic Jacksonville, Jacksonville, Fla.(E.A.P.); University of Pittsburgh, Pitts-burgh (J.B., G.Y.); Mayo Clinic, Rochester,Minn. (V.J.S., T.M.P., D.W.V., R.B.J., W.L.L.,J.N.I.); Allegheny General Hospital, Pitts-burgh (C.E.G., N.W.); Sidney Kimmel Com-prehensive Cancer Center at Johns Hop-kins University, Baltimore (N.E.D.), theCancer Research Network, Plantation, Fla.(E.T.-C.); Angeles Clinic and Research Insti-tute, Santa Monica, Calif. (S.M.); NorrisCotton Cancer Center, Dartmouth–Hitch-cock Medical Center, Lebanon, N.H.(P.A.K.); Cancer Therapeutics Branch, Na-tional Cancer Institute, Bethesda, Md.(S.M.S.); Kaiser Permanente Medical Cen-ter Northern California, Vallejo (L.F.); On-cology Associates of Cedar Rapids, CedarRapids, Iowa (L.A.K.); University of Pitts-burgh Cancer Institute, Pittsburgh (V.G.V.);Wichita Community Clinical Oncology Pro-gram, Wichita, Kans. (S.R.D.); AultmanHealth Foundation, Canton, Ohio (E.P.M.);and Genentech, South San Francisco, Calif.(P.M.K.). Address reprint requests to Dr.Geyer at the Allegheny Cancer Center, 5thFl., 320 E. North Ave., Pittsburgh, PA15212, or at cgeyer@wpahs.org.

Drs. Romond and Perez contributed equallyto the article.

N Engl J Med 2005;353:1673-84.

Copyright © 2005 Massachusetts Medical Society.

We present the combined results of two trials that compared adjuvant chemotherapywith or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.

methods

The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxoru-bicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with thesame regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel(group 2). The North Central Cancer Treatment Group trial N9831 compared threeregimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A),the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), andthe same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel(group C). The studies were amended to include a joint analysis comparing groups 1 andA (the control group) with groups 2 and C (the trastuzumab group). Group B was ex-cluded because trastuzumab was not given concurrently with paclitaxel.

results

By March 15, 2005, 394 events (recurrent, second primary cancer, or death before re-currence) had been reported, triggering the first scheduled interim analysis. Of these,133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48;P<0.0001). This result crossed the early stopping boundary. The absolute difference indisease-free survival between the trastuzumab group and the control group was 12 per-cent at three years. Trastuzumab therapy was associated with a 33 percent reduction inthe risk of death (P=0.015). The three-year cumulative incidence of class III or IV con-gestive heart failure or death from cardiac causes in the trastuzumab group was 4.1percent in trial B-31 and 2.9 percent in trial N9831.

conclusions

Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide im-proves outcomes among women with surgically removed HER2-positive breast cancer.

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

(clinicaltrials.gov numbers, NCT00004067 and NCT00005970.)

n engl j med 353;16

doc.guandang.net

october 20, 20051673

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email